Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 63 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Results first posted: Jan 15, 2026v63 Show 7 more changesShow less
    • Primary endpoints: 2 to 1
    • Enrollment target: 156 to 150
    • Interventions: Dasatinib (Drug), Laboratory Biomarker Analysis (Other), Pharmacological Study (Other), Quality-of-Life Assessment (Other), Questionnaire… to Dasatinib (Drug)
    • Secondary endpoints expanded, about 14 words
    • Study description expanded, about 117 words
    • Study arms: 2 to 1
    • Eligibility criteria shortened, about 2 words
  2. Re-verified, no change to tracked fieldsv62
  3. Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates changed from estimate of Nov 30, 2024 to Mar 14, 2025
    v61
  4. 6 versions Re-verified since Dec 6, 2022, no change to tracked fieldsv55-v60
  5. Primary and study completion dates: Nov 30, 2022 to Nov 30, 2024v54
Show 40 earlier versionsHide 40 earlier versions
  1. Primary completion date: Nov 30, 2021 to Nov 30, 2022v53
  2. Primary completion date: Nov 30, 2020 to Nov 30, 2021
    • Enrollment target: estimated 150 to confirmed 156
    • Study completion date: Nov 30, 2020 to Nov 30, 2022
    v52
  3. Primary and study completion dates: Nov 30, 2019 to Nov 30, 2020
    • Eligibility criteria shortened, about 12 words
    v51
  4. Study description revised
    • Collaborators: 2 to 1
    v50
  5. Re-verified, no change to tracked fieldsv49
  6. Primary endpoints: 1 to 2v48 Show 8 more changesShow less
    • Primary and study completion dates: Nov 2019 to Nov 30, 2019
    • Start date: Nov 2005 to Nov 8, 2005
    • Interventions: Dasatinib (BMS-354825) (Drug) to Dasatinib (Drug), Laboratory Biomarker Analysis (Other), Pharmacological Study (Other), Quality-of-Life Assessment (Other), Questionnaire…
    • Eligibility criteria expanded, about 13 words
    • Study description shortened, about 112 words
    • Study site revised
    • Collaborators: 1 to 2
    • Study title expanded, about 2 words
  7. Re-verified, no change to tracked fieldsv47
  8. Eligibility criteria revisedv46
  9. Re-verified, no change to tracked fieldsv45
  10. Primary completion date: Nov 2018 to Nov 2019
    • Study completion date: Nov 2019
    v44
  11. Re-verified, no change to tracked fieldsv43
  12. Primary completion date: Nov 2017 to Nov 2018
    • Eligibility criteria revised
    v42
  13. Primary completion date: Nov 2016 to Nov 2017
    • Study completion date: Nov 2016 to not stated
    v41
  14. Re-verified, no change to tracked fieldsv40
  15. Study description revised
    • Eligibility criteria expanded, about 5 words
    v39
  16. 3 versions Re-verified since Sep 11, 2014, no change to tracked fieldsv36-v38
  17. Trial status: Recruiting to Active, Not Recruiting
    • Study site revised
    v35
  18. Primary and study completion dates: Nov 2015 to Nov 2016v34
  19. Study description shortened, about 1 wordv33
  20. 3 versions Re-verified since Dec 3, 2013, no change to tracked fieldsv30-v32
  21. Study description shortened, about 4 wordsv29
  22. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v28
  23. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v27
  24. Eligibility criteria revisedv26
  25. Primary and study completion dates: Nov 2014 to Nov 2015
    • Eligibility criteria shortened, about 2 words
    v25
  26. Re-verified, no change to tracked fieldsv24
  27. Eligibility criteria expanded, about 2 wordsv23
  28. Eligibility criteria shortened, about 29 wordsv22
  29. Re-verified, no change to tracked fieldsv21
  30. Primary and study completion dates: Nov 2012 to Nov 2014
    • Eligibility criteria expanded, about 4 words
    v20
  31. 2 versions Re-verified since Nov 4, 2011, no change to tracked fieldsv18-v19
  32. Eligibility criteria expanded, about 1 wordv17
  33. Eligibility criteria expanded, about 35 words
    • Study description shortened, about 114 words
    v16
  34. Primary and study completion dates: Nov 2011 to Nov 2012v15
  35. Primary and study completion dates pushed to Nov 2011v14
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to learn if BMS-354825 (dasatinib) can help to control CML in chronic phase. The safety of this drug will also be studied.
Trial Details
NCT Number NCT00254423
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Related terms Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov